About this episode
Reactive oxygen species (ROS) sit at the center of modern cancer biology and the conversation around them is often wildly oversimplified. In this Deep Dive, Dr. Mike Belkowski explains why ROS are not “bad molecules,” but cellular signaling messengers that can be hijacked by tumors. The core framework is the one you need to remember: ROS has a dual role in cancer —moderate ROS can support tumor growth and therapy resistance, while excessive ROS can push cancer cells into programmed death (including ferroptosis).
You’ll learn the major ROS species (signaling vs damage), where ROS comes from (mitochondria, peroxisomes, ER, NOX enzymes + environmental sources), how tumors walk a redox tightrope using NRF2 to stay below toxic thresholds, and how redox biology controls angiogenesis, metastasis, drug resistance, and immune evasion. Finally, the episode lands on the mature therapeutic vision: personalized redox oncology — profiling a tumor’s “redox signature” to decide when to inhibit ROS signaling vs when to push ROS past the cancer cell’s tolerance threshold, often in combination with standard therapy.
(Educational content only, not medical advice.)
-
Article Discussed in Episode:
Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications
-
Key Quotes From Dr. Mike:
“ROS have a dual role in cancer."
“Moderate ROS can help tumors grow and resist therapy, while excessive ROS can push cancer cells into programmed cell death.”
“Mitochondria are not just energy factories, they’re redox generators and redox regulators.”
“The future vision is personalized redox oncology.”
“Cancer is a redox game.”
-
Key Points
ROS are signaling molecules, not just damage molecules; cancer hijacks the signaling.
Dual role: moderate ROS = pro-growth + resistance; excessive ROS = cell death.
Hydrogen peroxide (H₂O₂) is a key signaling ROS; hydroxyl radicals are the damage ROS.
Major endogenous sources: mitochondria (Complex I/III leak), peroxisomes, ER protein folding, NOX enzymes.
Redox balance is governed by NRF2 — protective in healthy cells, often weaponized by tumors.
Tumors live on a redox tightrope: high enough ROS to drive survival pathways, low enough to avoid self-destruction.
Moderate ROS can amplify survival networks (MAPK/ERK, PI3K-AKT-mTOR, HIF-1α, NF-κB, JAK-STAT, TGF-β).
Excess ROS can activate death programs: apoptosi
